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A B S T R A C T
Purpose
The combination of chemotherapy and trastuzumab is the standard of care for adjuvant treatment of 
human epidermal growth factor receptor 2–positive breast cancer. Two regimens have been widely 
adopted in the United States: doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (ACTH) 
and docetaxel, carboplatin, and trastuzumab (TCH). No head-to-head comparison of these regimens 
has been conducted in a clinical trial, and existing trial data have limited generalizability to older 
patients.
Methods
We used SEER-Medicare data from 2005 to 2013 to compare outcomes of ACTH versus TCH 
among patients age older than 65 years. Propensity score matching was used to balance cohort 
characteristics between treatment arms. Outcomes included toxicity-related hospitalization, sur-
vival, and trastuzumab completion. Data from 1,077 patients receiving ACTH or TCH were analyzed, 
and the propensity-matched subsample included 416 women.
Results
There was a significant shift toward TCH over time, with 88% of patients receiving ACTH in 2005 
compared with 15% by 2011. Among propensity score–matched patients, we found no difference 
between regimens in health care use overall or for chemotherapy-related adverse events (ACTH, 
34% v TCH, 36.5%; P = .46). Patients receiving TCH were significantly more likely to complete 
trastuzumab (89% v 77%; P = .001). There was no difference in 5-year breast cancer–specific 
survival (ACTH, 92% v TCH, 96%; hazard ratio, 2.08; 95% CI, 0.90 to 4.82) or overall survival.
Conclusion
Among a matched sample of older patients, ACTH compared with TCH was not associated with 
a higher rate of serious adverse events or hospitalizations, but it was associated with less com-
pletion of adjuvant trastuzumab. We did not detect a difference in 5-year survival outcomes for ACTH 
compared with TCH. In the context of limited evidence in older patients, selection between these 
two regimens on the basis of concerns about differential toxicity or efficacy may not be appropriate.
J Clin Oncol 35:3298-3305. 
INTRODUCTION
Over the past two decades, the combination of
chemotherapy and the monoclonal antibody
trastuzumab has become the standard of care for
systemic therapy of human epidermal growth
factor receptor 2 (HER2) –positive breast cancer.
Two adjuvant trastuzumab-based regimens have
been widely adopted in the United States. The
combination of doxorubicin, cyclophosphamide,
paclitaxel, and trastuzumab (ACTH) was ap-
proved for adjuvant use in 2006 on the basis of
the NSABP (National Adjuvant Breast and Bowel
Project) B31 and NCCTG (North Central Cancer
Treatment Group) 9831 studies.1,2 Docetaxel com-
bined with carboplatin and trastuzumab (TCH) was
approved in 2008 on the basis of the BCIRG (Breast
Cancer International Research Group) 006 study.3,4
Although less intensive regimens have subsequently
emerged for lower-risk patients and are being
evaluated for older patients,5,6 and dual biologic
therapy including pertuzumab has been incorporated
into neoadjuvant regimens,7,8 ACTH and TCH
remain the standard of care for most women
with HER2-positive breast cancer.
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Most information available to clinicians choosing between
ACTH and TCH comes from a single randomized trial, BCIRG
006, a three-arm study in which both trastuzumab-containing
regimens were compared against chemotherapy alone. Although
not designed to compare ACTH with TCH, the study demon-
strated an absolute difference of 1.6% in 10-year breast cancer–
specific survival between the trastuzumab-containing arms fa-
voring ACTH, which was not statistically significant.9 Conversely,
a difference in cardiac toxicity was noted favoring TCH, with 0.4%
of patients receiving TCH and 2.0% of patients receiving ACTH
developing congestive heart failure. No head-to-head clinical trial
has compared ACTH and TCH in terms of efficacy or toxicity, nor
is one anticipated. Moreover, patients represented in these pivotal
studies had a median age of approximately 49 years, were mostly
white, and had few comorbidities, limiting their relevance in the
choice between ACTH and TCH for older and frailer women. Prior
research has shown surprisingly low rates of adjuvant trastuzumab
use among older, particularly minority womenwith HER2-positive
breast cancer, possibly because of these data limitations.10,11 The
impact of regimen choice on the likelihood of completing tras-
tuzumab is also unknown. Given emerging evidence that shorter
trastuzumab duration adversely affects outcomes,12,13 the effect of
regimen choice on adherence may be an important factor to
consider when selecting an initial regimen.
Comparative-effectiveness research as defined by the Institute
of Medicine is “the generation and synthesis of evidence that
compares the benefits and harms of alternative methods to prevent,
diagnose, treat and monitor a clinical condition, or to improve the
delivery of care.”14(p203) Where prospective randomized data are
unlikely to become available, rigorous observational studies can
inform clinical care by offering information about the outcomes of
treatment from large populations of community-dwelling patients
receiving different treatments for clinically similar disease.
The linkage of the SEER cancer registry network to insurance
claims from Medicare provides a national population-based sample
of older patients for observational comparative-effectiveness studies
of cancer treatments. We sought to compare the toxicities, com-
pletion rates, and disease outcomes of older women receiving ACTH
and TCH in real-world settings, employing propensity-matching
methods to mitigate selection bias. We also sought to characterize
the patterns of use of ACTH and TCH over time and on the basis of
patient characteristics.
METHODS
From the SEER-Medicare database,15 we identified women age 66 years or
older with incident stage I to III breast cancer between 2005 and 2011
(Fig 1). Participants were required to have a claim for trastuzumab
(Healthcare Common Procedure Coding System code J9355) within 1
year of diagnosis, a cancer surgery within 6 months of diagnosis, and no
neoadjuvant chemotherapy. We excluded women with missing in-
formation on Tor N stage or a second primary cancer within 1 year and
those who were not continuously enrolled in fee-for-service Medicare
(parts A and B; no health maintenance organizations) for 12 months
before diagnosis. Participants were required to remain enrolled until
completion of adjuvant trastuzumab or 18 months after trastuzumab
initiation. Finally, we developed a claims-based algorithm to identify
users of TCH or ACTH (Appendix Fig A1, online only). Following an
intent-to-treat approach, patients were not required to complete all
doses or to receive all doses on time. Patients who switched treatments
were excluded.
Completion of Trastuzumab Therapy
We defined completion as having at least 270 days of trastuzumab
within 540 days of the first claim.12 Women were considered ongoing tras-
tuzumab users until they experienced a gap of more than 90 days between
claims. Fewwomen (4.4%) hadmore than 90-day gaps followed by resumption
of therapy. Days covered by trastuzumab were defined as the time between
treatment dates, with a maximum of 21 days of coverage for each claim.
Chemotherapy-Related Toxicities
We evaluated inpatient and outpatient claims within 6 months of
beginning chemotherapy with primary or secondary diagnoses for the
following chemotherapy-related adverse events16,17: nausea, emesis, diarrhea,
mucositis, dehydration, malnutrition, fever, urinary tract infection, pneu-
monia, infections, anemia, neutropenia, headache, heart failure or cardio-
myopathy, cerebrovascular accident or transient ischemic attack, deep-vein
thrombosis or pulmonary embolism, neuropathy, liver or kidney failure,
fractures, and delirium. For conditions likely to be present before chemo-
therapy (heart failure, cerebrovascular accident or transient ischemic
attack, neuropathy, liver or kidney failure), the condition was only
counted as a toxicity if the patient had no claims for the same condition
within 365 days before chemotherapy. We separately evaluated toxicities
recorded in the hospital or emergency department from those in out-
patient visits. For the multivariable model, the primary outcome was any
emergency or inpatient visit for a chemotherapy-related adverse event
within 6 months of chemotherapy initiation. This model was performed
on the propensity-matched subsample and further adjusted for age, race,
marital status, poverty, geographic region, rurality, comorbidity, number
of heart-related conditions, diagnosis year, and tumor characteristics. All
evaluable patients had at least 6 months of claims after chemotherapy
initiation.
Survival
We measured survival as the days alive from diagnosis through De-
cember 2013. To define overall survival (OS), we used the SEER vital status
file. For recurrence-free survival, we used a claims-based proxy with high
sensitivity and specificity for identifying secondary breast cancer events.18
For breast cancer–specific survival (BCSS), deaths were attributed to breast
cancer if it was listed as the cause of death in the SEER record or if the patient
had an algorithm-defined recurrence followed by death.19 Patients were
censored at death resulting from other cause (for cancer end points), dis-
enrollment, end of claims data in December 2013, or 5 years postdiagnosis.
Because patients receiving TCH on average were diagnosed later than those
receiving ACTH, we included diagnosis period as a matching variable.
Covariates
We measured age, race, marital status, SEER region, urban area,
hormone receptor status, tumor size, tumor grade, nodal involvement,
surgery, and radiation therapy. We also created census-tract poverty level
measures. Using the Medicare Chronic Conditions Warehouse, we mea-
sured heart failure, hyperlipidemia, hypertension, ischemic heart disease,
and myocardial infarction.20 Finally, we measured overall medical comor-
bidity using the Klabunde-adapted Charlson score.21
Analysis
We used propensity score matching to create comparable cohorts of
women receiving ACTH and TCH regimens on the basis of pretreatment
characteristics. Propensity score adjustment is a widely accepted approach
to control for selection bias in observational studies.22,23 We con-
sidered alternative propensity-adjustment approaches, including inverse
phreg procedure to determine equality of ACTH and TCH strata (SAS
Institute, Cary, NC).
RESULTS
Predictors of Regimen Choice
The full study cohort (Table 1) included 1,077 women. Before
propensity score matching, patients receiving ACTH tended to be
younger, reside in the North Central and Northeast SEER regions,
and have less comorbidity. Patients receiving ACTH also had
higher stage, higher rates of hormone receptor negativity, andmore
grade 3 tumors. Practice patterns changed significantly over time;
ACTH use dropped from 88% of patients in 2005 to only 15% in
2011 (Fig 2). After matching, patient characteristics were similar
between arms, except for slightly more breast-conserving surgeries
without radiation therapy performed in the TCH arm. The pro-
portionally small match rate was a function of the shift toward
TCH over time and the necessary inclusion of diagnosis period as
a matching variable. Detailed information regarding the distri-
bution of patients among ACTH, TCH, and other chemotherapy
ACTH or TCH chemotherapy regimen
(n = 1,077)
Women diagnosed alive at age  66 years
 with stage I to III primary breast cancer between
 2005 and 2011 with  1 claim for
 trastuzumab within 365 days of diagnosis
(N = 3,495)
Died within 365 days of diagnosis
(n = 105)
Survived  365 days after diagnosis
(n = 3,390)
 1 month of HMO coverage or
  1 month without A and B coverage
(n = 454)
FFS Medicare (A and B; no HMO) from 12 
months before 18 months after
start of trastuzumab (or death)
No surgery or surgery > 6 months after 
diagnosis (n = 268)
Mastectomy or breast-conserving
surgery within 6 months of diagnosis
Chemotherapy before surgery
(n = 186)
No chemotherapy before surgery
(n = 2,482)
Unknown tumor size or nodal




Diagnosed with a second primary within 1 year
(n = 140)
No second primary within
1 year of diagnosis
Nonstandard chemotherapy regimen
(n = 1,250)
Fig 1. Patient distribution diagram. ACTH,
doxorubicin, cyclophosphamide, paclitaxel, and
trastuzumab; FFS, fee for service; HMO, health
maintenance organization; NOS, not other-
wise specified; TCH, docetaxel, carboplatin, and
trastuzumab.
probability of treatment weighting (IPTW), but chose the matching 
approach for primary analysis because it produced the best balance 
between treatment arms regarding the measured covariates evalu-
ated using standardized adjusted mean differences, with a standardized 
adjusted mean difference greater than 10% indicating acceptable 
balance. We performed sensitivity analyses using IPTW for all survival 
end points to take advantage of the larger size of the full sample. We 
created the propensity score using logistic regression, with regimen 
assignment as the dependent variable. The model was fit with covariates 
on the basis of clinical judgment and known confounders from prior 
literature, including age, race, marital  status, geographic region, ru-
rality, census tract–level poverty, Charlson comorbidity score, number 
of heart-related conditions, stage, hormone receptor status, grade, and 
diagnosis year. Patient cases were matched using the Greedy matching 
algorithm.
Among patients in the propensity score–matched sample, we used 
multivariable modified Poisson regression24,25 to assess the association 
between regimen (ACTH or TCH) and postchemotherapy inpatient, 
observation, and emergency room visits. We also used Poisson regression 
to examine the effect of regimen on likelihood of completing trastuzumab.
We compared Kaplan-Meier curves of 5-year survival rates for ACTH 
and TCH in the matched cohort. All surviving patients were censored at 
end of follow-up death, disenrollment, or 5 years postdiagnosis. We used 
the SAS LIFETEST procedure to produce the Kaplan-Meier curves and the
Table 1. Characteristics of Full and Propensity Score–Matched Cohorts
Characteristic













Age group, years* .0846 .8016
65-74 84.1 79.8 81.7 80.8
$ 75 15.9 20.2 18.3 19.2
Race* .7336 .1801
Black 6.30 7.16 5.77 5.29
Other 8.22 7.16 6.73 12.0
White 85.5 85.7 87.5 82.7
Married or domestic partner* 55.1 55.2 .9681 52.4 50.0 .6238
Residents living below poverty line, %* .1191 .9358
0-4.99 33.7 33.3 33.7 33.7
05.0-9.99 30.1 25.0 29.3 26.9
10.0-19.99 24.4 27.9 25.0 26.0
$ 20 11.8 13.8 12.0 13.5
SEER region* , .001 .8761
North Central 16.4 9.69 18.3 16.8
Northeast 26.0 15.4 21.6 24.0
South 24.4 28.9 26.4 24.0
West 33.2 45.9 33.7 35.1
Metropolitan area residence* .3445 .8849
Less urban/rural 12.6 10.7 13.5 13.0
Urban 87.4 89.3 86.5 87.0
Charlson score for 1 year prior* .0046 .7877
0 74.2 65.0 72.6 74.0
1 18.6 22.9 18.8 16.3
2+ 7.12 12.1 8.65 9.62
No. of heart-related chronic conditions* .0170 .9037
0 37.3 32.0 38.5 37.5
1 28.2 24.4 24.5 26.4
$ 2 34.5 43.5 37.0 36.1
Derived AJCC stage group , .001 .8449
I 15.6 36.1 19.7 18.8
IIA 35.3 31.3 37.0 33.7
IIB 21.6 14.2 17.3 18.8
III 27.4 18.4 26.0 28.8
Hormone receptor status* .0090 .4297
Negative 45.8 37.5 46.2 42.3
Positive 54.2 62.5 53.8 57.7
AJCC tumor size* , .001 .6652
T1a-c 39.2 52.7 42.3 38.0
T2 50.7 39.6 48.6 52.4
T3 10.1 7.72 9.13 9.62
AJCC nodes involved* , .001 .8353
N0 35.1 57.4 43.3 40.4
N1 41.4 26.7 33.2 34.6
N2/N3 23.6 15.9 23.6 25.0
Tumor grade* .0975 .3156
Not poor 26.8 31.7 28.4 24.0
Poor/unknown 73.2 68.3 71.6 76.0
Diagnosis year* , .001 .6123
2005-2006 49.6 6.18 20.2 19.7
2007 20.0 12.5 26.9 23.1
2008-2011 30.4 81.3 52.9 57.2
Locoregional treatment .0133 .0593
BCS and radiation therapy 7.40 13.2 6.73 12.5
BCS only 37.3 36.9 39.9 31.7
Mastectomy 55.3 49.9 53.4 55.8
$ 270 days of trastuzumab , .001 .0010
Complete 77.0 87.9 77.4 89.4
Incomplete 23.0 12.1 22.6 10.6
Abbreviations: ACTH, doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab; AJCC, American Joint Committee on Cancer; BCS, breast-conserving surgery; TCH,
docetaxel, carboplatin, and trastuzumab.
*Included in propensity matching.
among ACTH users (ACTH, 77%; TCH, 89%; P = .001). Among
patients completing more than 270 days, the median number of
days covered was 371 for both ACTH and TCH. In multivariable
propensity score–matched analysis, receiving ACTH was an in-
dependent predictor of noncompletion of maintenance trastu-
zumab (relative risk, 0.86; 95% CI, 0.80 to 0.93). Other predictors
of noncompletion included age $ 75 years and Charlson comor-
bidity score of 2+. Race was not an independent predictor of
completion.
Survival
In the overall cohort, 88% of ACTH users and 93% of TCH
users were alive at 5 years (hazard ratio [HR], 1.41; 95% CI, 0.94
to 2.11); in the matched subset, 5-year OS was 90% for ACTH
users and 92% for TCH users (HR, 1.22; 95% CI, 0.63 to 2.35).
Five-year BCSS in the overall cohort was 90% in ACTH users and
96% in TCH users (HR, 2.14; 95% CI, 1.29 to 3.53). In the
propensity score–matched sample, 5-year BCSS was 92% in the
ACTH group and 96% in the TCH group (HR, 2.08; 95% CI, 0.90
to 4.82).
We performed a sensitivity analysis limited to matched pa-
tients who completed trastuzumab to explore the hypothesis
that the lack of survival difference between treatment arms
might be attributable to lower rates of trastuzumab completion
among patients receiving ACTH. Among patients who com-
pleted trastuzumab, 5-year BCSS was 93% in the ACTH group
and 97% in the TCH group (HR, 2.45; 95% CI, 0.85 to 7.04).
We performed sensitivity analyses using an IPTW propensity
approach for all survival end points to use data from the entire
cohort (N = 1,077). This approach also found no significant
difference between treatment arms in BCSS (HR, 1.45; 95% CI,
0.98 to 2.16) or OS (HR, 1.00; 95% CI, 0.72 to 1.39) but with
greater precision in the effect estimates. A comparison of the
effect estimates from the full cohort and propensity-matched
and IPTW models is included in Appendix Table A2 (online
only).
Survival curves for the propensity-matched sample are shown
in Figure 3. Sensitivity analyses of the full cohort and matched
subcohort using the alternative end points of OS and recurrence-









































Fig 2. Trends in use of trastuzumab-
containing regimens by year; patient cases
of breast cancer treated with doxorubicin,
cyclophosphamide, paclitaxel, and trastu-
zumab (ACTH) or docetaxel, carboplatin,
and trastuzumab (TCH) from 2005 to 2011
(N = 1,077).
regimens or single-agent trastuzumab is presented in Appendix 
Table A1 (online only) and in previously published work.10
Toxicity of Therapy
In the full study cohort, claims for neutropenia and anemia 
were more common in patients receiving ACTH (ACTH: 
neutropenia, 57%; anemia, 59% v TCH: neutropenia, 45%; 
anemia, 46%; P , .01), whereas claims for dehydration were 
more common among those receiving TCH (36% v 24%; P , .01). 
After matching, there were no significant differences in the 
overall frequency of chemotherapy-related adverse events. 
Although claims for incident heart failure were more common 
in matched patients receiving ACTH (7.2% v 3.9%), this 
finding did not reach statistical significance. We found evidence 
of postchemotherapy acute myeloid leukemia in claims for 
fewer than 1% of patients, divided proportionally among 
those receiving ACTH and TCH. Because of small cell sizes, 
exact numbers of cases of acute myeloid leukemia cannot be 
presented.
Health care use related to adverse events was relatively 
common and similar between groups. Hospital stays related to 
adverse events within 6 months of beginning therapy occurred in 
21% of ACTH users and 24% of TCH users in the overall cohort 
(P = .26). When emergency and observation visits were included, 
34% of patients receiving ACTH and 36.5% of those receiving 
TCH used hospital services during the period (P = .46). Patterns 
of use among the propensity-matched sample were similar to 
those of the overall cohort (data not shown). In multivariable 
propensity score–matched analysis, there was no significant 
difference in the adjusted likelihood of the composite outcome of 
an emergency or inpatient visit within 6 months of chemo-
therapy initiation between patients receiving ACTH and TCH. 
We performed a sensitivity analysis limiting the outcome to visits 
with a chemotherapy-related event as the primary diagnosis; 
results were similar.
Completion of Therapy
In the overall cohort, 77% of patients receiving ACTH and 
88% of patients receiving TCH completed adjuvant trastuzumab. 
In the matched subset, completion rates were significantly lower
DISCUSSION
In this national study of older women, we found no significant
differences in health care use for chemotherapy-related adverse
events between ACTH and TCH users. However, patients re-
ceiving TCH were significantly more likely to complete a full year
of trastuzumab, even after limiting our sample to those who were
well matched on measured characteristics. Among matched pa-
tients, BCSS and OS did not differ significantly between regimens.
Surprisingly, there was a trend toward higher BCSS among matched
patients receiving TCH for clinically similar disease, in contrast
to the trend toward improved survival for ACTH observed in
a previous clinical trial. However, the gap between TCH and
ACTH was not statistically significant after propensity matching
to account for measured differences in patient characteristics
between treatment arms.
Previous research has reported underuse of trastuzumab in
older women,10,11 widespread use of nonstandard regimens,16
noncompletion of therapy,26 and significant toxicities,26 but no
previous study has compared the effectiveness of ACTH and TCH
in older women. Comparative-effectiveness studies can fill a crucial
knowledge gap when clinical trial data have limited applicability to
a patient population or when a comparative trial is unlikely to be
conducted. Clinical trials of adjuvant trastuzumab1,3,27 have in-
cluded patients with a median age of 49 years. Women older than
age 60 years made up approximately 15% of participants, and those
older than age 70 years or with cardiac conditions were largely ex-
cluded. Although our study is constrained by the inherent limitations
of observational research, we believe that it adds valuable information
regarding tolerability and effectiveness of ACTH and TCH in older
women.
There are several possible reasons why this study did not find
differences in toxicity or efficacy between regimens. First, the null
result may simply confirm the results of the BCIRG 006 trial,
in which there was no significant survival advantage for the
anthracycline-containing regimen. Alternative explanations must
be considered. The lower completion rate of trastuzumab among
ACTH users might decrease the effectiveness of this regimen.
Although we did not detect a survival advantage for ACTH in the
subset of patients who completed trastuzumab, this sensitivity
208 192 147 0
208 195 142 0
ACTH
TCH


































Log-rank P = .0866
161 150 118 0
186 174 128 0
ACTH
TCH
















0 500 1,000 1,500
B
Log-rank P = .5542
208 192 147 0
208 195 142 0
ACTH
TCH
















0 500 1,000 1,500
C
161 150 118 0
186 174 128 0
ACTH
TCH
Days Alive After Diagnosis (5-year cap)
















0 500 1,000 1,500
D
Fig 3. Kaplan-Meier curves for 5-year survival outcomes of propensity score–matched patients by regimen. (A, B) Breast cancer–specific and (C, D) overall survival in (A,
C) all patients and (B, D) completers. ACTH, doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab; TCH, docetaxel, carboplatin, and trastuzumab.
analysis was underpowered to conclude whether ACTH was
superior to TCH in patients who completed their full year of
therapy. We were not able to examine the dose-intensity or dose
density of the chemotherapy agents in detail. It is possible that
more chemotherapy dose reductions or delays occurred in the
ACTH arm, reducing effectiveness. Given that the marginal
benefit of anthracyclines is greater in higher-risk patients,28 we
might expect to see less difference between treatment groups if
our study contained lower-risk patients compared with those in
BCIRG 006. Our sample included a similar proportion of hor-
mone receptor–positive patients (56% v 54%) but a slightly
higher proportion of node-negative patients (42% v 29%) than
BCIRG 006.3 Lastly, the analytic approach used cannot account
for unmeasured confounders that may have been associated with
treatment selection and that might affect survival. For instance,
patients receiving ACTH may have been perceived as higher risk
by their providers on the basis of characteristics not included in
cancer registry data, such as the speed with which the cancer
presented, lymphovascular invasion, extranodal extension, or
inadequate surgical management.
This study has several limitations common to observational
analyses. Insurance claims cannot measure the full extent of
toxicity or quality-of-life effects of treatment. It is certainly possible
that one regimen is superior to the other in terms of nonlethal
long-term effects or quality of life. Similarly, retrospective ob-
servational studies cannot evaluate recurrence or adjudicate cause
of death with the same level of detail as a clinical trial, introducing
possible misclassification of survival events. Although we accounted
for selection bias and potential confounders of the treatment-
outcome relationships using statistical methods, residual con-
founding resulting from unmeasured factors may have remained
and not been addressed by propensity score adjustment. Because
pharmacy claims were not uniformly available, we were unable
to control for the effect of antiestrogen therapy in hormone
receptor–positive patients. Our sample size was limited, par-
ticularly among matched patients, and thus underpowered to
determine whether the slight numeric advantage in survival
among patients receiving TCH represented a true difference in
efficacy. Finally, the assignment of treatment regimen in claims
data necessarily relies on algorithms that may not correctly
assign the intended treatment in all cases; however, the pro-
portion of patients in our sample receiving ACTH and TCH, as
well as other chemotherapy regimens or single-agent trastuzu-
mab, is similar to that reported previously in a similar SEER-
Medicare cohort by Freedman et al,16 using an independently
developed algorithm. We did find a slightly lower proportion of
patients receiving ACTH, likely because of our inclusion of 2
additional years of more recent data.
Among older women with HER2-positive breast cancer,
ACTH compared with TCH was not associated with more
chemotherapy-related adverse events, but it was associated
with a lower rate of completion of adjuvant trastuzumab. We
did not find a significant difference in survival outcomes
between regimens. In the context of limited evidence in older
patients, selection between these two regimens in older
women on the basis of concerns for differential toxicity or
efficacy may not be appropriate. As adjuvant therapy for
HER2-positive breast cancer evolves to include de-escalated
chemotherapy and dual-targeted therapy, it is important to
continue to evaluate real-world toxicity and effectiveness,
supplementing and extending the contributions of prospec-
tive clinical trials.
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Patients receiving  one dose trastuzumab
(NDC code J9355) and meeting
 other study criteria
Patients not meeting criteria
for either standard regimen
Search for all claims between 120 days before
and 7 days after first trastuzumab for:
doxorubicin (HCPCS C9415, J9000, J9001), carboplatin
(HCPCS J9045), paclitaxel (HCPCS C9127, C9431,







Two doxorubicin claims  60 days apart
First doxorubicin 120 days before first
trastuzumab
Paclitaxel or docetaxel claim within 
7 days of first trastuzumab
No carboplatin claims
No claim for other chemotherapy agents
within 365 days
Two carboplatin claims  60 days apart
First carboplatin claim and first docetaxel
claim within  7 days of first trastuzumab
No doxorubicin claim
No claim for other chemotherapy agents
within 365 days
Fig A1. Treatment assignment algorithm. ACTH, doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab; HCPCS, Healthcare Common Procedure Coding System;
NDC, National Drug Code; TCH, docetaxel, carboplatin, and trastuzumab.
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Fig A2. Kaplan-Meier curves for 5-year survival outcomes of full unmatched cohort (N = 1,077). (A, B) Breast cancer–specific and (C, D) overall survival in (A, C) all patients
and (B, D) completers. ACTH, doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab; TCH, docetaxel, carboplatin, and trastuzumab.
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Fig A3. Kaplan-Meier curves for 5-year recurrence-free survival outcomes of (A, B) propensity score–matched cohort (n = 416) and (C, D) full cohort (N = 1,077) in (A, C) all
patients and (B, D) completers. ACTH, doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab; TCH, docetaxel, carboplatin, and trastuzumab.
Table A1. Distribution of Chemotherapy Regimens
Regimen
Chemotherapy Regimen Assignment Rules for SEER-Medicare Cohort (N 5 2,327)
Receiving at Least 1 Dose of Adjuvant Trastuzumab Within 1 Year of Diagnosis
(rules are hierarchical*) No. %
Standard (n 5 1,177 patients) 1. ACTH
1st doxorubicin claim within 120 days of the 1st trastuzumab claim AND
a paclitaxel or docetaxel claim within 6 7 days of 1st trastuzumab claim AND
21 doxorubicin claims within 60 days AND
no carboplatin claims AND
no trastuzumab prior to first doxorubicin
365 15.69
2. TCH
1st carboplatin claim within 6 7 days of the 1st trastuzumab claim AND
any docetaxel claim within 6 7 days of 1st trastuzumab claim AND
21 carboplatin within 60 days AND
no doxorubicin claims
712 30.60
Nonstandard (n 5 1,250) 3. Anthracycline-based, not meeting ACTH definition
Any doxorubicin or epirubicin claim, not meeting criteria for group 1
254 10.92
4. Carboplatin-based, not meeting TCH definition
Any carboplatin claim, not meeting criteria for group 2
158 6.79
5. Taxane-based
Any paclitaxel or any docetaxel, no anthracycline or carboplatin
432 18.56
6. Other chemotherapy agents 72 3.09
7. Single-agent trastuzumab only 334 14.35
Abbreviations: ACTH, doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab; TCH, docetaxel, paclitaxel, and trastuzumab.
*In a similar cohort of 2,106Medicare beneficiaries receiving adjuvant trastuzumab over a slightly earlier time period (2005-2009), Freedman et al17 reported 459 patients
(21.8%) receiving doxorubicin-cyclophosphamide plus taxanes, 624 patients (29.6%) receiving TCH, and 318 (15.1%) receiving trastuzumab as a single agent, with the
remainder receiving other chemotherapy combinations.
Table A2. Comparison of Full Cohort, Propensity-Matched, and Propensity-Weighted Survival Models
Survival
Multivariable Model, No
Propensity (n 5 1,077)
Propensity-Matched
Model (n 5 416)
IPTW Propensity
Model (n 5 1,077)
HR 95% CI HR 95% CI HR 95% CI
BCSS 2.14 1.29 to 3.53 2.08 0.90 to 4.82 1.45 0.98 to 2.16
OS 1.41 0.94 to 2.11 1.22 0.63 to 2.35 1.00 0.72 to 1.39
NOTE. Comparison of multivariable, propensity-matched, and propensity-weighted survival mode results. The multivariable model was adjusted for age, race, marital
status, geographic region, rurality, census-tract level poverty, Charlson comorbidity score, number of heart-related conditions, stage, hormone receptor status, grade, and
diagnosis year, and the propensity scores for matched and IPTW models were created using the same covariates. BCSS, 5-year breast cancer–specific survival; HR,
hazard ratio; IPTW, inverse probability of treatment weighting; OS, 5-year overall survival.
